ArticleScientific reports2025
Secondary metabolites of Minutisphaera thailandensis and Hongkongmyces kokensis revealed by LC-QTOF-MS and their antimicrobial and cytotoxic activities.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Green extraction approach for green microalga Tetraselmis tetrahele: Enhanced phenolic yield and bioactivity via Ultrasound-Assisted extraction.Ultrasonics sonochemistry · 2026Article
- Antibacterial, antibiofilm, and metabolomic profiling of the novel freshwater fungi Longipedicellata megafusiformis and Wicklowia fusiformispora.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The mycelial extracts of two novel fungal species, Minutisphaera thailandensis and Hongkongmyces kokensis, were investigated for their antimicrobial, cytotoxic, and secondary metabolite profiles to assess their potential as sources of bioactive natural products. LC-QTOF-MS profiling revealed that the mycelial extracts contained a greater diversity of metabolites compared to the culture supernatants. M. thailandensis demonstrated strong antibacterial activity against Bacillus subtilis (MIC = 62.25 µg/mL; inhibition zone = 20.12 ± 0.21 mm), Staphylococcus epidermidis (125.00 µg/mL; 19.32 ± 0.15 mm), and Staphylococcus aureus subsp. aureus (125.00 µg/mL; 19.08 ± 0.12 mm). H. kokensis was active against Pseudomonas aeruginosa (16.45 ± 0.28 mm) and Escherichia coli (16.87 ± 0.36 mm). Both fungi also exhibited antifungal activity against Candida albicans (zones = 13.38-17.29 mm). Fifteen metabolites were identified in the mycelial extract of M. thailandensis while 16 compounds were found in those obtained from H. kokensis. These included alkaloids (norharman, indole-3-carboxylic acid), fatty acid amides (oleamide, stearamide), sphingolipids (phytosphingosine, 3-ketosphinganine), polyketides (chaetochromin), and unsaturated fatty acids (linoleic acid), among others. Both fungi shared 4-hydroxycoumarin, carapin-8(9)-ene, and phytosphingosine, while chaetochromin and 13-epi-12-oxo-phytodienoic acid were unique to H. kokensis. Antimicrobial and cytotoxic activities may be attributed to the presence of bioactive compounds including phytosphingosine, 4-hydroxycoumarin, chaetochromin, linoleic acid, and oleamide, all of which possess reported pharmacological effects. M. thailandensis exhibited stronger cytotoxicity against SW480 (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.